{
    "clinical_study": {
        "@rank": "127618", 
        "acronym": "PROTECT 1", 
        "arm_group": [
            {
                "arm_group_label": "Peg-Filgrastim", 
                "arm_group_type": "Active Comparator", 
                "description": "During each chemotherapy cycle eligible patients receive Peg-Filgrastim s.c. post chemotherapy application."
            }, 
            {
                "arm_group_label": "LA-EP2006", 
                "arm_group_type": "Experimental", 
                "description": "During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application."
            }
        ], 
        "brief_summary": {
            "textblock": "The study will assess the efficacy of LA-EP2006 compared to Peg-Filgrastim with respect to\n      the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy\n      in breast cancer patients."
        }, 
        "brief_title": "Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta\u00ae", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Neutropenic Complications", 
            "Breast Cancer Patients Treated With Myelosuppressive Chemotherapy"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically proven breast cancer\n\n          -  eligible for six cycles of neoadjuvant or adjuvant chemotherapy\n\n        Exclusion Criteria:\n\n          -  concurrent or prior chemotherapy for breast cancer\n\n          -  concurrent or prior anti-cancer treatment for breast cancer such as endocrine\n             therapy, immunotherapy, monoclonal antibodies, and/or biological therapy\n\n          -  concurrent prophylactic antibiotics\n\n          -  previous therapy with any G-CSF (granulocyte-colony stimulating factor) product\n\n        Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "318", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01735175", 
            "org_study_id": "LA-EP06-301", 
            "secondary_id": "2011-004532-58"
        }, 
        "intervention": [
            {
                "arm_group_label": "LA-EP2006", 
                "description": "Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.", 
                "intervention_name": "LA-EP2006", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Peg-Filgrastim", 
                "description": "Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.", 
                "intervention_name": "Peg-Filgrastim", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lenograstim"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prevention of neutropenic complications in breast cancer patients", 
            "Pegfilgrastim,", 
            "G-CSF,", 
            "neutropenia,", 
            "breast cancer,", 
            "myelosuppressive chemotherapy,", 
            "supportive care"
        ], 
        "lastchanged_date": "September 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kursk", 
                    "country": "Russian Federation"
                }, 
                "name": "Regional Budgetary Healthcare Institution \"Kursk Regional Clinical Oncological Dispensary\" of Committee Healthcare of Kursk Territory, Russia"
            }
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta\u00ae in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy", 
        "overall_official": {
            "affiliation": "Sandoz Biopharmaceuticals", 
            "last_name": "Karsten Roth, Dr.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Mean duration of severe neutropenia, defined as number of consecutive days with Grade 4 neutropenia.", 
            "measure": "Mean duration of Grade 4 neutropenia during Cycle 1 of chemotherapy", 
            "safety_issue": "Yes", 
            "time_frame": "21 days (Cycle 1 of chemotherapy treatment)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01735175"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess the safety of LA-EP2006 and Peg-Filgrastim.", 
                "measure": "Incidence of febrile neutropenia", 
                "safety_issue": "Yes", 
                "time_frame": "4 months"
            }, 
            {
                "measure": "Incidence, occurrence and severity of (serious) adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "10 months"
            }
        ], 
        "source": "Sandoz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sandoz", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}